Efficacy of a topical formulation containing fipronil, moxidectin and praziquantel (Banni(3®)) for the control of gastrointestinal helminths of zoonotic importance in naturally infected cats

含有氟虫腈、莫昔克丁和吡喹酮的局部用药制剂(Banni(3®))对自然感染猫体内具有人畜共患重要性的胃肠道蠕虫的控制效果

阅读:4

Abstract

Gastrointestinal helminthiases in domestic cats are a significant concern for both animal and human health due to the zoonotic potential of parasites such as Ancylostoma spp., Toxocara spp. and Dipylidium caninum. The increasingly close coexistence between humans and cats in urban environments increases the need for effective and practical strategies for parasite control. We evaluated the efficacy of an antiparasitic formulation based on fipronil, moxidectin and praziquantel (Banni(3®)) for topical application. A total of 38 cats infected by the helminths of interest were evaluated and the helminths were found to belong to more than one genus. Coproparasitological evaluations were performed on days D-7 and D-2 (pre-treatment) and D+7 and D+14 (post-treatment) using the modified McMaster technique to count eggs per gram of feces (EPG). In the case of D. caninum, proglottids and ovigerous capsules were also analyzed. Of the animals tested, 38 were positive for Ancylostoma spp., 20 for Toxocara spp. and 22 for D. caninum. Six animals had infections by helminths of a single genus, 22 by two and 10 by all three genera. After treatment, the results indicated efficacy of 97.4% (D+7) and 99% (D+14) for Ancylostoma spp., 96.12% (D+7) and 97.84% (D+14) for Toxocara spp., and 100% (D+7 and D+14) for D. caninum. The topical formulation Banni(3) (fipronil, moxidectin, and praziquantel) demonstrated high efficacy in controlling Ancylostoma spp., Toxocara spp., and D. caninum in naturally infected cats. The results confirm its potential as a practical and effective alternative for the control of zoonotic helminths.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。